(Q51837455)

13 April 2018

title

A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. (English)

1 reference

13 April 2018

1 reference

M Giusti

1

1 reference

13 April 2018

F Sibilla

2

1 reference

13 April 2018

C Cappi

3

1 reference

13 April 2018

M Dellepiane

4

1 reference

13 April 2018

F Tombesi

5

1 reference

13 April 2018

E Ceresola

6

1 reference

13 April 2018

C Augeri

7

1 reference

13 April 2018

E Rasore

8

1 reference

13 April 2018

F Minuto

9

1 reference

13 April 2018

publication date

1 July 2005

1 reference

13 April 2018

Journal of Endocrinological Investigation

published in

1 reference

13 April 2018

volume

28

1 reference

13 April 2018

issue

7

1 reference

13 April 2018

page(s)

599-608

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1007/bf03347258

exact match

0 references

cites work

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Recurrent and/or metastatic thyroid cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Clinical review 156: Recombinant human thyrotropin and thyroid cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Health profiles and quality of life of 518 survivors of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Persistent psychological distress in patients treated for endocrine disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347258

Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience

21 January 2018

1 reference

12 December 2020

Papillary and follicular thyroid carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma

1 reference

12 December 2020

Guidelines for the management of thyroid cancer

1 reference

12 December 2020

Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).

1 reference

12 December 2020

Assessment of quality of life in recently post-menopausal women on dopaminergic therapy for pathological hyperprolactinaemia

1 reference

12 December 2020

Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency

1 reference

12 December 2020

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

1 reference

12 December 2020

A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer

1 reference

12 December 2020

Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients

1 reference

12 December 2020

1. Improvement criteria in drug trials with neurotic patients

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347258

1 reference

13 April 2018

1 reference

13 April 2018